InvestorsObserver
×
News Home

Do Analysts Agree on Xenon Pharmaceuticals Inc (XENE) Stock's Target Price?

Monday, October 05, 2020 01:13 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Agree on Xenon Pharmaceuticals Inc (XENE) Stock's Target Price?

Analysts who follow Xenon Pharmaceuticals Inc (XENE) on average expect it to add 98.62% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns the stock an Analyst Ranking of 76, which means it ranks higher than 76 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.8
Wall Street analysts are rating XENE a Strong Buy today. Find out what this means to you and get the rest of the rankings on XENE!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.

Investors Observer takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Xenon Pharmaceuticals Inc Stock Today?

Xenon Pharmaceuticals Inc (XENE) stock has gained 6.04% while the S&P 500 is flat 0% as of 1:10 PM on Monday, Oct 5. XENE is higher by $0.66 from the previous closing price of $10.92 on volume of 78,065 shares. Over the past year the S&P 500 is up 13.94% while XENE is higher by 40.19%. XENE lost -$0.97 per share the over the last 12 months.

Click Here to get the full report on Xenon Pharmaceuticals Inc (XENE) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App